A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs. Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy
The goal of this clinical research study is to learn if adding daratumumab to lenalidomide and dexamethasone can help to control multiple myeloma (MM) better than lenalidomide and dexamethasone alone. The safety of this drug combination will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 12/22/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: